Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT05064540 · View on ClinicalTrials.gov ↗

Study Summary

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).

Interventions

  • DEVICE Alto Abdominal Stent Graft System
  • DEVICE FDA Approved EVAR AAA Graft Systems

Study Locations (20)

Florida

  • Jacksonville Center for Clinical Research — Jacksonville
  • Radiology and Imaging Specialists — Lakeland
  • Baptist Hospital of Miami, Miami Cardiac and Vascular Institute — Miami

Arkansas

  • Washington Regional Medical Center — Fayetteville
  • Central Arkansas Veterans Healthcare System — Little Rock

California

  • The Regents of the University of California, San Diego — La Jolla
  • Veterans Affairs San Diego Healthcare System — San Diego

New York

  • Icahn School of Medicine at Mount Sinai — New York
  • Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health) — Staten Island

Ohio

  • The Cleveland Clinical Foundation — Cleveland
  • The Ohio State University — Columbus

Alabama

  • Huntsville Hospital — Huntsville

Arizona

  • University of Arizona — Tucson

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2021-09-20
Est. Completion 2031-03
Phase NA

Sponsor

Endologix

10 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05064540

The ClinicalTrials.gov registry entry for NCT05064540 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endologix, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with AAA - Abdominal Aortic Aneurysm appearing as the primary indexed condition, and to 2 interventions — of which Alto Abdominal Stent Graft System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05064540 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Florida, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05064540 about?

NCT05064540 is a clinical study titled "JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization". Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, a...

What is the current status of trial NCT05064540?

This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2021-09-20. Estimated completion is 2031-03.

What conditions does trial NCT05064540 study?

This clinical trial studies the following conditions: AAA - Abdominal Aortic Aneurysm, AAA. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05064540?

The interventions under investigation include: Alto Abdominal Stent Graft System (DEVICE), FDA Approved EVAR AAA Graft Systems (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05064540?

This trial is sponsored by Endologix, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05064540 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial